| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.07 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.07 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.08 |